SEC Form 4 · accession 0000912282-26-000832
Quince Therapeutics, Inc. · QNCX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Lamond
Director
Period of report
Jun 11, 2026
Accepted (ET)
Jun 15, 2026 · 5:57 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001662774
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option (Right to Buy)F1 | $0.947 | Jun 11, 2026 | A | 2,700 | A | — | Jun 11, 2036 | Common Stock | 2,700 | 2,700 | D |
Explanation of responses
- F1100% of the shares subject to this stock option will vest on the one-year anniversary of the grant date.